Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
TENUATE is an oral tablet small-molecule approved in 1975 for weight management. The specific mechanism of action and indications are not disclosed in available data. This is a legacy product with a long commercial history.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team size and investment likely being reassessed or consolidated.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old
PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
Synbiotic to Attenuate Resorption of the Skeleton
Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Worked on TENUATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sanofi is hiring 1 role related to this product
TENUATE offers limited direct career momentum given zero linked job openings and LOE-approaching status. Positions on this team focus on defending market share, optimizing pricing, and managing transition to generics rather than driving growth.